Improving susceptibility of neuroendocrine tumors to radionuclide therapies: personalized approaches towards complementary treatments.

"Competing Interests: The authors have declared that no competing interest exists."

"This work was supported by the German Research Foundation [Deutsche Forschungsgemeinschaft (DFG)] within the CRC/Transregio 205/2, Project number: 314061271 - TRR 205 “The Adrenal: Central Relay in Health and Disease” (to all authors). Due to massive reductions in the costs of next generation sequencing, multi-gene panel genetic diagnostics are performed on a routine basis in the Western world. Especially for patients with PPGLs, genetic screening for mutations in known susceptibility genes is recommended to identify hereditary causes and to better manage the risk of metastatic disease . Additionally, several countries are running precision oncology-based cancer trials, including the National Institutes of Health in the USA and the Molecularly Aided Stratification for Tumor Eradication (MASTER) program in Germany. Personalized PRRT approaches could be incorporated in such existing infrastructures. The proposed combinational treatments might become important, especially, in the context of rare diseases, where dedicated clinical trials for new agents are difficult to perform."